MU­NICH— Cy­to­ki­net­ics’ heart drug Myqor­zo could gain ex­pand­ed ap­proval next year, po­ten­tial­ly dou­bling its mar­ket reach, af­ter de­tailed re­sults backed the drug’s use in...

MU­NICH— CRISPR Ther­a­peu­tics’ gene edit­ing can­di­date showed mixed dura­bil­i­ty re­sults a year af­ter pa­tients were dosed, ac­cord­ing to ear­ly-stage da­ta pre­sent­ed Fri­day at the...

The FDA ap­proved Roivant’s der­mato­myosi­tis drug bre­poc­i­tinib on Thurs­day, the first ma­jor reg­u­la­to­ry nod that could ush­er in a multi­bil­lion-dol­lar rev­enue stream for the hub-and-spoke...

Gilead Sci­ences' HIV treat­ment ar­se­nal is get­ting big­ger.

The lead­ing drug­mak­er in the four-decade epi­dem­ic gained an­oth­er FDA stamp of ap­provalon Thurs­day. This time...

MU­NICH— The sur­prise fail­ure of a high-pro­file study of As­traZeneca and Io­n­is Phar­ma­ceu­ti­cals’ Wain­ua can be at­trib­uted to pa­tients in the tri­al al­so tak­ing...

→ Dai­ichi Sankyo will re­tool its com­mer­cial or­ga­ni­za­tion, and Ken Kellerwill be at the cen­ter of it all as chief com­mer­cial­iza­tion of­fi­cer. On April...